Literature DB >> 22146319

MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression.

Xiang-yu Zhong1, Jian-hua Yu, Wei-guang Zhang, Zhi-dong Wang, Qin Dong, Sheng Tai, Yun-fu Cui, Hui Li.   

Abstract

MicroRNAs (miRNAs) are involved in the development of most cancers. However, few studies have been conducted to determine their relationship to biliary tract cancer (BTC). Farnesoid X receptor (FXR) has been reported to be a tumor suppressor for hepatocellular carcinoma and breast cancer; but few studies have focused on its correlation with BTC. In this study, we identified miR-421 as a potential regulator of FXR expression. We found that their expression amount was inversely correlated as FXR was aberrantly down-regulated in both primary tumor specimens and cell lines; while miR-421 was significantly up-regulated. Ectopic expression of miR-421 significantly decreased FXR protein concentration in BTC cells and promoted cell proliferation, colony formation and migration in vitro. Furthermore, a decrease in miR-421 expression induced G(0)/G(1) cell cycle arrest. In conclusion, our study identified microRNA-421 functions as an oncomiR in BTC by targeting FXR. This finding may provide a novel therapeutic strategy for treatment of biliary tract cancer.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22146319     DOI: 10.1016/j.gene.2011.11.028

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  35 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 2.  MicroRNAs and benign biliary tract diseases.

Authors:  Sergio A Gradilone; Steven P O'Hara; Tetyana V Masyuk; Maria Jose Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 3.  MicroRNAs in biliary diseases.

Authors:  Patricia Munoz-Garrido; Maite García-Fernández de Barrena; Elizabeth Hijona; Miguel Carracedo; José J G Marín; Luis Bujanda; Jesús M Banales
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

4.  Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Gregory Dyson; Fazlul H Sarkar
Journal:  Epigenetics       Date:  2012-07-18       Impact factor: 4.528

Review 5.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

6.  Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors.

Authors:  Nidhi Singh; Manisha Yadav; Abhishek Kumar Singh; Harish Kumar; Shailendra Kumar Dhar Dwivedi; Jay Sharan Mishra; Anagha Gurjar; Amit Manhas; Sharat Chandra; Prem Narayan Yadav; Kumaravelu Jagavelu; Mohammad Imran Siddiqi; Arun Kumar Trivedi; Naibedya Chattopadhyay; Sabyasachi Sanyal
Journal:  Mol Endocrinol       Date:  2014-03-05

7.  Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

Authors:  Alexander Baraniskin; Stefanie Nöpel-Dünnebacke; Brigitte Schumacher; Christian Gerges; Thilo Bracht; Barbara Sitek; Helmut E Meyer; Guido Gerken; Alexander Dechene; Jörg F Schlaak; Roland Schroers; Christian Pox; Wolff Schmiegel; Stephan A Hahn
Journal:  Dig Dis Sci       Date:  2014-01-31       Impact factor: 3.199

Review 8.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

9.  MicroRNAs in Cholangiopathies.

Authors:  Steven P O'Hara; Sergio A Gradilone; Tetyana V Masyuk; James H Tabibian; Nicholas F LaRusso
Journal:  Curr Pathobiol Rep       Date:  2014-09-01

Review 10.  Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

Authors:  Swetha Rudraiah; Xi Zhang; Li Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.